Ferroptosis Signaling in Endometrial Cancer: Emerging Molecular Vulnerabilities

Author Name : Hidoc internal team

Oncology

Page Navigation

Abstract

Endometrial cancer is the most common gynecologic malignancy in high-income countries, and its incidence is increasing alongside obesity, metabolic disease, and population aging. Although surgery and molecular classification have improved risk assessment, advanced, recurrent, and treatment-resistant disease remains a major clinical challenge. Ferroptosis is an iron-dependent form of regulated cell death characterized by phospholipid peroxidation, depletion of antioxidant defenses, and catastrophic membrane injury. Increasing evidence indicates that endometrial cancer cells exhibit distinctive vulnerabilities in iron handling, lipid metabolism, redox regulation, and DNA damage responses that may be exploited therapeutically. Key regulators include system xc−, glutathione peroxidase 4, acyl-CoA synthetase long-chain family member 4, ferritin, transferrin receptor 1, the Nrf2 pathway, and the mevalonate-coenzyme Q10 axis. Molecular alterations involving mismatch repair, polymerase epsilon, p53, phosphatidylinositol 3-kinase signaling, and hormonal pathways may influence ferroptosis sensitivity. This review summarizes the biological basis, clinical relevance, diagnostic implications, therapeutic opportunities, risks, and future research priorities surrounding ferroptosis signaling in endometrial cancer.

Introduction

Endometrial cancer comprises a biologically diverse group of tumors arising from the uterine endometrium. Contemporary classification integrates histopathology with molecular features, particularly mismatch repair deficiency, microsatellite instability, abnormal p53 signaling, and polymerase epsilon alterations. This framework has refined prognosis and supported individualized treatment, but it has also highlighted the complexity of therapeutic resistance. Ferroptosis has emerged as a potentially important mechanism linking tumor metabolism, oxidative stress, immune activity, and treatment response.

Unlike apoptosis, ferroptosis is driven by the iron-catalyzed oxidation of polyunsaturated fatty acids within cellular membranes. Tumor cells may become unusually dependent on antioxidant systems because rapid proliferation, mitochondrial stress, oncogenic signaling, and hypoxic tumor regions increase reactive oxygen species. In endometrial cancer, this dependence may create therapeutic windows in which malignant cells are selectively sensitized to ferroptotic death while normal tissues retain greater metabolic flexibility. However, ferroptosis-directed treatment remains investigational, and clinical translation requires careful biomarker development and toxicity evaluation.

Epidemiology / Disease Burden

The burden of endometrial cancer is substantial and continues to rise in many regions. Obesity, insulin resistance, diabetes, reduced physical activity, and longer life expectancy contribute to increasing incidence. Most patients present with abnormal uterine bleeding and are diagnosed at an early stage, when hysterectomy with appropriate staging is frequently curative. Nevertheless, aggressive histologic subtypes, extensive disease, and recurrence account for a disproportionate share of mortality.

Advanced or recurrent endometrial cancer may develop resistance to platinum-based chemotherapy, hormonal therapy, immune checkpoint inhibition, or targeted treatments. Serous, carcinosarcoma, undifferentiated, and p53-abnormal tumors often have particularly unfavorable outcomes. The increasing prevalence of obesity also creates a biologically relevant context for ferroptosis research because adipose tissue, inflammation, altered lipid availability, and iron metabolism can influence oxidative vulnerability. These epidemiologic and metabolic trends support investigation of ferroptosis as both a prognostic mechanism and a therapeutic target.

Pathophysiology

Ferroptosis depends on the interaction of iron availability, lipid peroxidation, and inadequate antioxidant protection. Transferrin receptor 1 facilitates iron uptake, while ferritin stores intracellular iron in a relatively inert form. Ferritinophagy, mediated in part by nuclear receptor coactivator 4, can release iron and increase the labile iron pool. Ferrous iron participates in Fenton chemistry, generating highly reactive radicals that accelerate membrane lipid oxidation. Consequently, tumors with increased iron uptake, defective iron sequestration, or impaired iron export may be more susceptible to ferroptosis induction.

The cystine-glutamate antiporter system xc−, formed primarily by SLC7A11 and SLC3A2, imports cystine for glutathione synthesis. Glutathione is required by glutathione peroxidase 4, which detoxifies phospholipid hydroperoxides and protects membranes from oxidative collapse. Inhibition of system xc−, depletion of glutathione, or direct suppression of glutathione peroxidase 4 can therefore promote ferroptosis. ACSL4 and lysophosphatidylcholine acyltransferase 3 enrich membranes with oxidizable polyunsaturated phospholipids, whereas monounsaturated lipid production may provide relative protection.

Additional defense systems include ferroptosis suppressor protein 1, which supports coenzyme Q10-dependent radical trapping, and the GTP cyclohydrolase 1-tetrahydrobiopterin pathway. Nrf2 transcriptional activity can increase antioxidant capacity, promote glutathione production, and regulate iron-handling genes. Oncogenic PI3K-AKT-mTOR signaling, p53 activity, estrogen-related signaling, and inflammatory cytokines may modify these pathways. The resulting ferroptosis phenotype is therefore not determined by a single gene; it reflects a dynamic balance between iron metabolism, lipid composition, antioxidant reserves, mitochondrial function, and microenvironmental stress.

Risk Factors

Established risk factors for endometrial cancer include obesity, chronic unopposed estrogen exposure, polycystic ovary syndrome, early menarche, late menopause, nulliparity, tamoxifen exposure, diabetes, and hereditary mismatch repair syndromes. These factors may also influence ferroptosis biology. Adiposity can alter circulating lipids, inflammatory mediators, insulin signaling, and iron distribution. Hyperinsulinemia may activate PI3K-AKT-mTOR pathways, supporting tumor growth and potentially increasing dependence on antioxidant defenses.

Inherited or acquired alterations in TP53, PTEN, PIK3CA, ARID1A, mismatch repair genes, and polymerase epsilon may create distinct redox states. Prior chemotherapy and radiotherapy can produce oxidative stress and select resistant subclones with enhanced antioxidant capacity. These observations do not establish that conventional risk factors directly cause ferroptosis resistance, but they provide a rationale for integrating metabolic and molecular characteristics into future risk models.

Clinical Features

Clinical presentation is not specific to ferroptosis signaling. The most common symptom is abnormal uterine bleeding, including postmenopausal bleeding, intermenstrual bleeding, prolonged menstruation, or unusually heavy menstrual flow. Pelvic discomfort, discharge, anemia, or constitutional symptoms may occur in more advanced disease. Symptoms related to distant metastases depend on the involved organs.

From a biological perspective, tumors with high oxidative stress may exhibit rapid progression, treatment resistance, or adaptation to hypoxic and nutrient-limited conditions. These associations remain under active investigation and should not be used as standalone clinical indicators of ferroptosis dependence. Histology, stage, molecular subtype, and patient comorbidities remain the established determinants of management.

Diagnosis

Evaluation begins with clinical assessment, pelvic examination when appropriate, and endometrial sampling. Hysteroscopy or directed biopsy may be useful when initial sampling is nondiagnostic. Pathologic assessment determines histologic subtype, grade, depth of myometrial invasion, lymphovascular space involvement, and cervical or extrauterine extension. Imaging with pelvic magnetic resonance imaging, computed tomography, or other staging modalities is selected according to clinical circumstances.

Molecular evaluation should include mismatch repair and microsatellite instability testing, p53 assessment, and polymerase epsilon analysis when indicated by contemporary classification systems. These results guide prognosis and eligibility for immunotherapy or other targeted approaches. Ferroptosis biomarkers are not yet recommended for routine diagnosis. Candidate measures include SLC7A11, GPX4, ACSL4, transferrin receptor 1, ferritin, lipid peroxidation products, iron-storage proteins, and gene-expression signatures. Their clinical utility is limited by intratumoral heterogeneity, assay standardization challenges, and the dynamic nature of redox biology.

Treatment & Management

Standard treatment remains stage- and risk-adapted surgery, generally involving hysterectomy with bilateral salpingo-oophorectomy and selective nodal assessment. Adjuvant radiation, chemotherapy, hormonal therapy, immunotherapy, or targeted treatment is considered according to histology, molecular subtype, recurrence risk, and patient fitness. Carboplatin and paclitaxel remain important systemic agents, while immune checkpoint inhibitors and combination strategies have expanded options for advanced or recurrent disease.

Ferroptosis-based treatment could complement existing approaches in several ways. Inhibition of system xc− may reduce glutathione availability, whereas GPX4 inhibition may directly disable a central membrane-protection mechanism. Agents that increase labile iron, promote ferritin degradation, alter lipid remodeling, or suppress coenzyme Q10-dependent protection may further enhance ferroptosis. Radiation and selected chemotherapies can increase reactive oxygen species and might be combined with ferroptosis-inducing strategies. However, dose optimization is essential because normal organs, particularly the liver, kidney, nervous system, and hematopoietic compartment, also require redox protection.

Clinical implementation should be individualized and preferably restricted to controlled trials until validated biomarkers and safety data are available. Potential risks include hepatotoxicity, nephrotoxicity, anemia, neuropathy, inflammatory injury, and unpredictable interactions with immunotherapy. Nutritional status, iron deficiency, chronic inflammation, renal function, and concomitant antioxidant supplements may influence treatment response. Clinicians should therefore avoid unproven self-directed iron manipulation or high-dose supplementation.

Recent Advances / Emerging Therapies

Preclinical studies are examining small molecules that inhibit GPX4, SLC7A11, or related antioxidant pathways, as well as compounds that disrupt iron storage and lipid metabolism. Nanoparticle-based delivery systems are being investigated to concentrate ferroptosis-inducing agents within tumor tissue and reduce systemic exposure. Combination approaches involving PI3K-AKT-mTOR inhibition, DNA damage response inhibition, radiotherapy, endocrine therapy, or immune checkpoint blockade are of particular interest because these treatments may expose metabolic weaknesses or increase oxidative pressure.

The tumor microenvironment is an important frontier. Cancer-associated fibroblasts, macrophages, endothelial cells, adipocytes, and infiltrating lymphocytes can exchange lipids, cytokines, iron, and antioxidant metabolites. Ferroptosis may influence antitumor immunity by releasing danger-associated signals, although excessive tissue injury could also promote immunosuppression or chronic inflammation. Future trials should incorporate serial tumor sampling, circulating lipid and iron markers, pharmacodynamic measurements, and patient-reported outcomes. Biomarker-driven adaptive designs may identify the molecular subgroups most likely to benefit.

Guideline Recommendations

Current professional guidelines for endometrial cancer emphasize accurate histologic diagnosis, comprehensive staging, molecular classification, risk-adapted surgery, and evidence-based adjuvant or systemic therapy. No major guideline currently recommends ferroptosis inhibitors, ferroptosis biomarkers, or therapeutic iron manipulation as standard care. Management should therefore remain consistent with established national and international guidance, multidisciplinary review, and shared decision-making.

For clinical practice, ferroptosis findings are most relevant as a research framework for explaining resistance and identifying investigational treatment combinations. Participation in ethically approved clinical trials is appropriate for patients with advanced disease who meet eligibility criteria. Trial protocols should include rigorous monitoring for organ toxicity, hematologic effects, drug interactions, and changes in nutritional or iron status. Translational studies should distinguish a tumor-specific ferroptotic response from nonspecific oxidative damage.

Conclusion

Ferroptosis signaling represents a promising but not yet clinically established vulnerability in endometrial cancer. The convergence of iron metabolism, membrane lipid oxidation, glutathione dependence, GPX4 activity, Nrf2 regulation, and oncogenic signaling provides a biologically coherent explanation for differential treatment sensitivity. Its greatest potential may lie in molecularly selected combinations with chemotherapy, radiotherapy, targeted therapy, endocrine treatment, or immunotherapy. Progress toward clinical application will require standardized biomarkers, reliable pharmacodynamic assays, careful attention to tumor heterogeneity, and well-designed prospective trials. Until such evidence is available, ferroptosis should be regarded as an important translational research opportunity rather than a replacement for guideline-directed management.

Featured News
Featured Articles
Featured Events
Featured KOL Videos

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot